

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Various</b>				
Thrombocytopenia; thrombosis	Syk tyrosine kinase (SYK)	<p>A study in mice suggests that inhibiting SYK could help prevent heparin-induced thrombocytopenia and thrombosis. In a mouse model of heparin-induced thrombocytopenia, the SYK inhibitor PRT060318 prevented decreases in platelet counts and reduced thrombosis in the lungs compared with vehicle controls. Next steps include evaluating PRT060318 in additional preclinical models of heparin-induced thrombocytopenia.</p> <p>Portola Pharmaceuticals Inc.'s PRT062607, an oral SYK inhibitor that is a follow-on to PRT060318, is in Phase I testing for rheumatoid arthritis (RA).</p> <p>At least three other companies have SYK inhibitors in clinical or preclinical testing for various indications.</p> <p><b>SciBX 3(48); doi:10.1038/scibx.2010.1456</b>  <b>Published online Dec. 16, 2010</b></p>	Patented; available for partnering	<p>Reilly, M.P. <i>et al. Blood</i>; published online Nov. 18, 2010; doi:10.1182/blood-2010-03-274969</p> <p><b>Contact:</b> Michael P. Reilly, Thomas Jefferson University, Philadelphia, Pa.            e-mail: <a href="mailto:michael.reilly@jefferson.edu">michael.reilly@jefferson.edu</a></p>